Abstract
Twenty eight infants and children (3-63 months) with Kawasaki disease received intravenous immunoglobulins (IVIG) in a multicentric study: Veinoglobulin (Merieux, France) in 24 cases or Sandoglobulln (Sandoz, Switzerland) in 4 cases. The total amount administered was In the range 1-2.5g/Kg and varied from 1 to 5 daily infusions. In 16 cases the patients received 0.4 mg/Kg/day during 5 consecutive days. All of them were given orally acetylsalicylic acid 30 mg/Kg/day during a 2 month period. A dramatic improvement in the patients' general condition was observed, with resolution of fever within 48 hours. Hyperfibrinemia and hyperleucocytosis returned to normal in one week and incresed platelets within 2-3 weeks. An important feature was that follow-up echocardiograms over more than one year have demonstrated no coronary artery abnormalities. Five out of 6 children studied immunologlcally during the acute phase presented with a deficiency of circulating CD8 T cells with an increased CD4/CD8 ratio. High doses of IVIG were followed with an increase of serum IgM, CD8 T cells and a normalisation of CD4/CD8 ratio. High dosage IVIG represents the treatment of choice of Kawasaki syndrome; this activity focuses the deficiency of the immunoregulatory function in Kawasaki syndrome.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Borderon, J., Lebranchu, Y. 7. KAWASAKI SYNDROME, TREATMENT WITH INTRAVENOUS GAMMAGLOBULINS. Pediatr Res 24, 654 (1988). https://doi.org/10.1203/00006450-198811000-00029
Issue Date:
DOI: https://doi.org/10.1203/00006450-198811000-00029